Solural Pharma ApS is a Danish speciality pharma founded by Ann Fullerton and Peter G Nielsen in 2012.
Solural Pharma ApS formulation technology platform provides innovative oral products having unique benefits regarding efficacy, safety and convenience
Solural Pharma ApS uses its formulation technology platform to develop new innovative oral drug products that meet the need by the patients, the doctors and the society for the treatment of important medical conditions.
We use our strong expertise in all aspects of pharmaceutical development from our many years of experience in major pharmaceutical companies to develop new successful drug products.
Solural Pharma ApS has development capabilities on our own, or together with partners to develop new oral formulations, from concept idea until clinical proof of concept.
Solural Pharma ApS has own Development facilities:
- Product Development Laboratories
- Analytical Development Laboratories
- ICH Stability Testing Facilities
- GMP manufacturing facilities for oral products
Solural Pharma ApS is certified by the Danish Health Authorities for GMP manufacturing and Quality Control testing of new Investigational Medicine Products.
Solural Pharma ApS uses our expertise to offer high level consultancy and product development task for our customers and partners in the pharmaceutical industry.
We support CMC development and project management needs for our customers.
We offer product development expertise and has access to own proprietary technology platform for providing solutions for lipophilic and low soluble oral drugs.
It is the ambition of Solural Pharma ApS to grow and expand on the proprietary technology platform to become the preferred partner for new high-value, specialized oral pharmaceuticals.
It is our ambition to employ and work with highly professional and motivated people.
Solural Pharma is managed by:
CEO, Peter G Nielsen
Peter G Nielsen is a biochemist by training and has more than 25 years of experience in pharmaceutical Drug Development.
He started his drug development career as a head of analytical chemistry at Ferrosan A/S before he joined Novo Nordisk A/S, where he spend more than 20 years in different managerial position. His latest position was as corporate Vice President for all formulation research and development at Novo Nordisk A/S.
In 2007 he joined Lifecycle Pharma A/S as executive Vice President, overseeing all technical operations including Pharmaceutical Research and Development, QA/QC and manufacturing. In this role he accomplished to get several drug products through the development process to registration and also one product now approved by the FDA.
COO, Qualified Person, Ann Fullerton
Ann Fullerton holds a PhD in pharmacy and has more than 23 years experience in drug research and drug product development. She has more than 12 years of extensive leadership and management skills as line manager as well as strong project management skills at all stages of development.
From 2001 to 2006 she served as Head of Pharmaceutical Formulation at LEO Pharma having the responsibility for both formulation development, investigational drug supplies and packaging development.
From 2006 to 2008 she held a position as senior project manager at Curalogic, a small Danish biotech company where she was leading a project in clinical phase 3. From 2008 to 2012 she was responsible for Formulation and Technology Development at Veloxis Pharmaceuticals latest as Vice President.
She has published more than 40 scientific papers as well as several patent applications.
CTO, Bent Højgaard
Bent Højgaard holds a MSc in pharmacy. He has +27 years of experience in technological tablet product development including formulation development, process development, technology transfer and production of clinical trial products from employment within Ferrosan, Novo Nordisk and Veloxis
He has issued several patent applications. Bent Højgaard is responsible for all laboratory process development and manufacture of our new formulations.
Strategic and Scientific Advisors:
We are relying heavily on professional advisors within specific areas.
DMSC, PhD, Professor, Chief Oncologist, Head of Center for Cancer Research, Dept. of Oncology Herlev University Hospital, Denmark
MBA, Strategic Advisor Corporate Development. Based in the US (Boston area)
Lars Bo Kjerrumgaard
M.Sc. European Patent Attorney: Patent Strategy
Mads Friis Sørensen
M.Sc.,Pharmac,: Quality Assurance and Quality Audits
Gitte Løvgren Larsen
Attorney at law, Partner, Sirius Advokater: Legal Affairs
- 29 Jun 2016Exclusive license agreementSolural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting Technology....
- 16 Jul 2015First human dosing initiated by Oncoral PharmaOncoral Pharma ApS initiate first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma...
- 22 Apr 2015Certificate of GMP Compliance of a ManufacturerSolural Pharma ApS receives Certificate of GMP Compliance of a Manufacturer issued by the Danish Health and Medicines Authority ...
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
firstname.lastname@example.org for more
information about available positions.